Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 pilot/expansion study of GV101/OV888 in adults with symptomatic cerebral cavernous malformation hemorrhage
MOH_2024-09-30_013570Phase 2Completed
- Sponsor
- Graviton Biosciences
- Start
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of TDI01 in cerebral cavernous malformation (CCM), sponsored by Graviton Biosciences. Primary endpoints: Safety of GV101/OV888, Tolerability of GV101/OV888 and 3 more. Started Sep 2024; status: completed.
02
Drugs
TDI01
03
Conditions
cerebral cavernous malformation (CCM)
Beyond the preview
Go deeper on MOH_2024-09-30_013570.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2024-09-30_013570.